Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response By Ogkologos - August 3, 2026 101 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Neo-CheckRay study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC May 15, 2023 PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer October 29, 2019 Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... May 11, 2022 EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... November 19, 2024 Load more HOT NEWS CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder... Παρακολούθηση και Φροντίδα EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients...
